Title: Kolmar BNH’s HemoHim Gains FDA’s NAI Classification, Boosting Global Credibility
Seoul, South Korea—Kolmar BNH (KRX: 200130), the renowned manufacturer of HemoHim, an immune-support supplement, has significantly enhanced its international credibility by receiving notable certifications from both the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA).
Kolmar BNH has announced that its Sejong facility has been granted a “No Action Indicated” (NAI) classification following an exhaustive FDA inspection. This classification signifies that the FDA found no significant deficiencies within the facility, underlining Kolmar BNH’s commitment to maintaining superior manufacturing standards.
Receiving the NAI classification is a pivotal achievement for Kolmar BNH, especially for biotech investors focused on regulatory validation. This FDA acknowledgment alongside the endorsement from the TGA, further strengthens HemoHim’s standing in the competitive global health supplement market.
Such affirmations ensure investors of the efficacy and quality of products coming out of Kolmar BNH, increasing their potential revenue through trust and consumer acceptance internationally.
For more detailed information, please visit: [Business Wire Health: Pharmaceutical News](http://www.businesswire.com/portal/site/home/news/industry/?vnsId=31070).